Loading viewer...
investor_presentation
Format: PDF investor_presentation
EyePoint Pharmaceuticals presents its pipeline of intravitreal drug delivery candidates, including DURAVYU (vorolanib) for wet AMD and NPDR, and EYP-2301 (razuprotafib) for retinal diseases, leveraging its proprietary Durasert platform. The company reports $299M in cash with runway through Phase 3 wet AMD trial topline data in 2026.
presentation
investor_presentation
25 Pages
Samsung Electronics Co., Ltd.
Hanmi Financial 1Q24 Investor Presentation 2024
investor_presentationinvestor_presentation
48 Pages
Hanmi Financial Corporation